Cart
sales@molnova.com
AMG-1
CAS No. 913376-84-8
AMG-1( RON-IN-1 | SYN1143 )
Catalog No. M24953 CAS No. 913376-84-8
AMG-1 is a potent inhibitor of human RON and c-Met.In vitro?kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 147 | In Stock |
|
| 10MG | 221 | In Stock |
|
| 25MG | 374 | In Stock |
|
| 50MG | 555 | In Stock |
|
| 100MG | 789 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAMG-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionAMG-1 is a potent inhibitor of human RON and c-Met.In vitro?kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively.
-
DescriptionAMG-1 is a potent inhibitor of human RON and c-Met.In vitro?kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively.
-
In VitroSYN1143 (Compound I) (10-1000 nM; 1 h) inhibits c-Met-mediated signaling and functional activity in HT-29 and BxPC3 cells.SYN1143 (10-1000 nM; 1 h) inhibits RON-mediated signaling and functional activity in NIH3T3 RON and BxPC3 cells.SYN1143 (0.3-30 μM; 2 h or 3 d) inhibits c-Met signaling and cell proliferation in MC3T3-E1 and C3H10T1/2 cells.SYN1143 (0.3-2 μM; 4-12 d) potentiates osteogenic differentiation of precursor cells. Western Blot Analysis Cell Line:HT-29 and BxPC3 cells Concentration:10, 30, 100, 300, 1000 nM Incubation Time:1 hours Result:Inhibited HGF-mediated c-Met phosphorylation and downstream signaling in a dose-dependent manner in both cell lines.
-
In VivoSYN1143 (10-100 mg/kg; p.o. for 22 d) inhibits the growth of c-Met-dependent and constitutively active RON-expressing tumors in mice.SYN1143 (20-50 μg; transferred into calvarial defects) stimulates bone formation in critical-sized defects of mouse calvarial bone. Animal Model:Female CD1 nu/nu mice (6-8 weeks) bearing NIH3T3 TPR-Met s.c. tumors Dosage:10, 30, 100 mg/kg Administration:Oral gavage either once or twice daily for 22 days Result:Significantly inhibited tumor growth at doses of 30 or 100 mg/kg once daily or at 30 mg/kg twice daily.Completely inhibited tumor growth at a dose of 100 mg/kg once daily.
-
SynonymsRON-IN-1 | SYN1143
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met|RON
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number913376-84-8
-
Formula Weight556.58
-
Molecular FormulaC31H29FN4O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:90 mg/mL?(161.7 mM;?Need ultrasonic)
-
SMILESCC(C)(CN(C(C)=C(C(Nc(cc1)cc(F)c1Oc1ccnc2cc(OC)ccc12)=O)C1=O)N1c1ccccc1)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang Y, et, al. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 2008 Aug 15;68(16):6680-7.
molnova catalog
related products
-
Capmatinib
Capmatinib (INCB-28060, INC-280) is a highly potent, selective, ATP competitive inhibitor of c-MET kinase with IC50 of 0.13 nM.
-
Tyrosine kinase inhi...
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).
